Advertisement

Familial Cancer

, Volume 17, Issue 1, pp 23–30 | Cite as

A multi-gene panel study in hereditary breast and ovarian cancer in Colombia

  • A. M. Cock-RadaEmail author
  • C. A. Ossa
  • H. I. Garcia
  • L. R. Gomez
Original Article

Abstract

Germline mutations in BRCA1 and BRCA2 account for approximately 50% of inherited breast and ovarian cancers. Three founder mutations in BRCA1/2 have been reported in Colombia, but the pattern of mutations in other cancer susceptibility genes is unknown. This study describes the frequency and type of germline mutations in hereditary breast and/or ovarian cancer genes in a referral cancer center in Colombia. Eighty-five women referred to the oncogenetics unit of the Instituto de Cancerologia Las Americas in Medellin (Colombia), meeting testing criteria for hereditary breast and ovarian cancer syndrome (NCCN 2015), who had germline testing with a commercial 25-gene hereditary cancer panel, were included in the analysis. Nineteen patients (22.4%) carried a deleterious germline mutation in a cancer susceptibility gene: BRCA1 (7), BRCA2 (8), PALB2 (1), ATM (1), MSH2 (1) and PMS2 (1). The frequency of mutations in BRCA1/2 was 17.6%. One BRCA2 mutation (c.9246dupG) was recurrent in five non-related individuals and is not previously reported in the country. Seventeen mutation-carriers had a diagnosis of breast cancer (median age of diagnosis of 36 years) and two of ovarian cancer. All BRCA1 mutation-carriers with breast cancer had triple negative tumors (median age of diagnosis of 31 years). Variants of unknown significance were reported in 35% of test results. This is the first report of a multi-gene study for hereditary breast and/or ovarian cancer in a Latin American country. We found a high frequency and a wide spectrum of germline mutations in cancer susceptibility genes in Colombian patients, some of which were not previously reported in the country. We observed a very low frequency of known Colombian founder BRCA1/2 mutations (1.2%) and we found mutations in other genes such as PALB2, ATM, MSH2 and PMS2. Our results highlight the importance of performing multi-gene panel testing, including comprehensive BRCA1/2 analysis (full gene sequencing and large rearrangement analysis), in high-risk breast and/or ovarian cancer patients in Colombia.

Keywords

Hereditary breast and/or ovarian cancer Multi-gene cancer panels BRCA1 BRCA2 Latin America Hispanic 

Notes

Acknowledgements

This study was supported and funded by the Instituto de Cancerologia Las Americas and the Comité para el Desarollo de la Investigación—CODI, CPT 1229, Universidad de Antioquia. We also thank the team of the Instituto de Cancerologia Las Americas: Dr. Mauricio Borrero, Dr. Fernando Herazo, Dr. Gonzalo A. Angel, Dr. Rene Pareja, Dr. Gabriel J. Rendon, Dr. Luis J. Palacios, Dr. Maria E. Montoya, Dr. Diego M. Gonzalez, Dr. Luz D. Suarez, Dr. Alejo Jimenez, Dr. Eduardo Gutierrez, Dr. Leon D. Ortiz, Dr. Pedro A. Reyes, Dr. Adolfo L. Lopez, Dr. Aminta Perez, Dr. Franz Usuga, Dr. Isabel C. Duque, Dr. Lina M. Arbelaez, Dr. Joaquin P. Rueda, Dr. David A. Mosquera, Paula Arboleda, Alejandra Saldarriaga, Adine Carvajal, Viviana Sanchez, Angela Estrada and Tatiana Gutierrez.

Authors contributions

AMCR and AO drafted the manuscript. AMCR performed Genetic Counseling of the patients. All authors revised the article critically and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

AMCR received financial support from Gencell for attending the meeting “IARC 2016: Global Cancer, Ocurrence, Causes and Avenues to Prevention” in France and the “XIV Congreso Nacional y VIII Congreso Internacional de Genética Humana” in Colombia in 2016. The other co-authors declare that they have no conflict of interest.

Ethical approval

All procedures performed involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Foulkes WD (2008) Inherited susceptibility to common cancers. N Engl J Med 359:2143–2153CrossRefPubMedGoogle Scholar
  2. 2.
    Castéra L, Krieger S, Rousselin A et al (2014) Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet 22:1305–1313CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van der Groep P, van der Wall E, van Diest PJ (2011) Pathology of hereditary breast cancer. Cell Oncol (Dordr) 34: 71–88CrossRefGoogle Scholar
  4. 4.
    Walsh T, Casadei S, Lee MK et al (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108:18032–18037CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Daly MB, Pilarski R, Axilbund JE et al (2016) Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw 14:153–162CrossRefPubMedGoogle Scholar
  6. 6.
    Ferla R, Calò V, Cascio S et al (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(6):vi93–vi98PubMedGoogle Scholar
  7. 7.
    Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C et al (2015) Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer 121:372–378CrossRefPubMedGoogle Scholar
  8. 8.
    Ossa CA, Torres D (2016) Founder and recurrent mutations in BRCA1 and BRCA2 Genes in Latin American countries: state of the art and literature review. Oncologist 21:832–839CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Torres D, Rashid MU, Gil F et al (2007) High proportion of BRCA1/2 founder mutations in hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225–232CrossRefPubMedGoogle Scholar
  10. 10.
    Hernández JE, Llacuachaqui M, Palacio GV et al (2014) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia. Hered Cancer Clin Pract 12:11CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ruiz-Linares A, Adhikari K, Acuña-Alonzo V et al (2014) Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7342 individuals. PLoS Genet 10:e1004572CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Rojas W, Parra MV, Campo O et al (2010) Genetic make up and structure of Colombian populations by means of uniparental and biparental DNA markers. Am J Phys Anthropol 143:13–20CrossRefPubMedGoogle Scholar
  13. 13.
    Solano AR, Cardoso FC, Romano V et al (2016) Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice. Oncotarget. doi:  10.18632/oncotarget.10814 PubMedPubMedCentralGoogle Scholar
  14. 14.
    Alemar B, Herzog J, Brinckmann Oliveira Netto C et al (2016) Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genet. doi:  10.1016/j.cancergen.2016.06.008 Google Scholar
  15. 15.
    Gutiérrez-Enríquez S, de la Hoya M, Martínez-Bouzas C et al (2007) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 103:103–107CrossRefPubMedGoogle Scholar
  16. 16.
    Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425CrossRefPubMedGoogle Scholar
  17. 17.
    Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456CrossRefPubMedGoogle Scholar
  18. 18.
    Rodríguez AO, Llacuachaqui M, Pardo GG et al (2012) BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 124:236–243CrossRefPubMedGoogle Scholar
  19. 19.
    Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222–2233CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN (2015) The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat 154:441–453CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dean M, Boland J, Yeager M et al (2015) Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience 4:50CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vogel KJ, Atchley DP, Erlichman J et al (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25:4635–4641CrossRefPubMedGoogle Scholar
  23. 23.
    Weitzel JN, Lagos V, Blazer KR et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14:1666–1671CrossRefPubMedGoogle Scholar
  24. 24.
    Weitzel JN, Clague J, Martir-Negron A et al (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the clinical cancer genetics community research network. J Clin Oncol 31:210–216CrossRefPubMedGoogle Scholar
  25. 25.
    Lagos-Jaramillo VI, Press MF, Ricker CN, Dubeau L, Mai PL, Weitzel JN (2011) Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat 130:281–289CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Adhikari K, Mendoza-Revilla J, Chacón-Duque JC, Fuentes-Guajardo M, Ruiz-Linares A (2016) Admixture in Latin America. Curr Opin Genet Dev 41:106–114CrossRefPubMedGoogle Scholar
  27. 27.
    Lynce F, Isaacs C (2016) How far do we go with genetic evaluation? gene, panel, and tumor testing. Am Soc Clin Oncol Educ Book 35:e72–e78CrossRefPubMedGoogle Scholar
  28. 28.
    Bravo LE, García LS, Carrascal E, Rubiano J (2014) Burden of breast cancer in Cali, Colombia: 1962–2012. Salud Publica Mex 56:448–456CrossRefPubMedGoogle Scholar
  29. 29.
    Robledo JF, Caicedo, J.J, Suarez R.D (2005) Análisis de sobrevida en una cohorte de 1328 pacientes con carcinoma de seno. Revista Colombiana de Cirugía 20, 4–20Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Instituto de Cancerologia Las AmericasMedellinColombia
  2. 2.Facultad de MedicinaUniversidad de AntioquiaMedellinColombia
  3. 3.Instituto de CancerologíaMedellinColombia

Personalised recommendations